Actively Recruiting
Newborn Screening Program for Early Detection of Aromatic L-Amino Acid Decarboxylase Deficiency in Liguria, Italy
Led by Istituto Giannina Gaslini · Updated on 2026-10-16
16000
Participants Needed
10
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Aromatic L-amino acid decarboxylase deficiency AADC-D is a rare genetic condition that affects brain chemicals and can cause serious neurological and developmental issues in newborns. Early diagnosis is important to allow timely specialist care and evaluation for treatment options such as gene therapy. This study aims to develop a newborn screening program for AADC-D in the Liguria region of Italy and estimate how often the disease occurs in this population. The study will include about 16,000 newborns born in participating hospitals. After parents or legal caregivers give consent, blood samples will be collected using dried blood spot cards as part of the existing newborn screening routine. These samples will be tested with tandem mass spectrometry to measure 3-O-methyldopa 3-OMD, a marker that may indicate AADC-D. Samples with positive results will be retested, and if still positive, genetic testing of the DDC gene will confirm the diagnosis. Participants are involved only through the collection of blood samples during routine newborn screening. Researchers will evaluate 3-OMD levels, establish reference and cut-off values for screening, and assess the screening methods performance over two years. The study aims to support a reliable newborn screening program for early detection of AADC-D, enabling prompt identification and care of affected infants.
CONDITIONS
Brief Title
Newborn Screening and Early Diagnosis of AADC Deficiency in the Ligurian Population
Research Team
P
Pasquale Striano, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here